What people on Mounjaro actually experience — and what the evidence shows

You've heard the headline numbers. Here's what they mean for real people.

Most conversations about Mounjaro start with a striking statistic: in the SURMOUNT-1 trial, participants lost an average of around 20–21% of their body weight over 72 weeks at the 15mg dose. That figure comes from a rigorous clinical trial involving 2,539 adults, published in the New England Journal of Medicine, and it's genuinely impressive. But averages hide a range. Some people in that trial lost considerably more; others lost less. A handful lost very little. If you want to understand why Mounjaro doesn't work for some people, the short answer is that biology, adherence, starting weight and metabolic health all play a role, and no trial figure should be read as a personal guarantee.

What the data does show consistently is that the majority of people taking tirzepatide at a therapeutic dose lose a meaningful amount of weight. The question people most often follow up with is whether that weight stays off. Evidence on what happens to weight after stopping Mounjaro suggests that, for most, weight does return if the medicine is discontinued without sustained lifestyle changes in place, which is why the clinical guidance frames it as long-term treatment, not a short course.

The 2.5mg starting pen has one job: help your system adjust. Nausea and other gastrointestinal effects are most likely in those first few weeks, and keeping to smaller, lower-fat meals helps many people through it. By the time most people reach a higher maintenance dose, the GI effects have settled considerably.

What the day-to-day looks like (and the questions prescribers hear most

People on Mounjaro tend to report a quietening of what researchers call "food noise") the persistent, background preoccupation with eating that many people with obesity describe. Appetite falls, portion sizes shrink without a conscious battle, and energy levels often stabilise once the initial adjustment period passes. That's the GIP and GLP-1 dual mechanism at work: slowing gastric emptying, increasing feelings of fullness and moderating blood-sugar fluctuations after meals, as the NHS's patient information on tirzepatide explains.

Practically, the weekly injection fits into most routines without too much disruption. Many people pick the same day each week (Sunday evening, say, or Saturday morning before the weekly shop) and rotate the site between abdomen, thigh and upper arm. The pen stays in the fridge between uses. One thing worth knowing before you travel: there is a limited window for keeping the pen at room temperature, but you should check the patient information leaflet for the exact figure rather than relying on a general source, because the window is shorter than people expect.

A common question our prescribers hear is whether Mounjaro is only for people with a very high BMI, or whether it can suit people closer to the lower eligibility threshold. The licensed criteria allow treatment for adults with a BMI of 27 or above when a weight-related health condition is present, the picture for people at the lower end of the eligibility range is nuanced and worth reading before making assumptions. Lower BMI thresholds also apply for some ethnic backgrounds under UK guidance.

Side effects: what most people actually experience

The side-effect profile of Mounjaro is well-characterised from clinical trials and growing real-world data. Nausea is the most commonly reported effect, followed by diarrhoea, constipation, vomiting, indigestion and fatigue. These are overwhelmingly gastrointestinal and, for most people, peak in the first two to four weeks after starting or increasing the dose, then ease.

There are rarer but serious effects to know about. The MHRA highlighted acute pancreatitis as a known, infrequent but potentially serious risk across GLP-1 medicines, severe stomach pain spreading to the back, with or without vomiting, warrants urgent medical attention. Gallbladder-related symptoms and signs of dehydration after prolonged vomiting or diarrhoea are also worth acting on promptly. Suspected side effects can be reported directly to the MHRA via the Yellow Card scheme.

Women taking oral contraceptives should add a non-oral method of contraception for the first four weeks of treatment and for four weeks after each dose increase, tirzepatide's effect on gastric emptying can reduce pill absorption during that window. This is one of several safety considerations a prescriber works through before approving treatment. For a broader picture of how tirzepatide works and what to expect, our main medicine page covers the mechanism and clinical background in more depth.

How many people are taking Mounjaro, and what does that tell us?

Uptake has accelerated rapidly since NICE recommended tirzepatide for weight management in December 2024. The numbers of people now on Mounjaro in the UK are growing week on week, through both NHS routes and private prescribing. That scale matters for two reasons: it produces real-world data that supplements trial findings, and it has created significant demand that has put supply under pressure at various points.

It has also attracted counterfeit products. The MHRA has seized large quantities of fake weight-loss pens sold through unverified online channels. Anyone buying Mounjaro should confirm the pharmacy holds a current GPhC registration, which is publicly searchable at the GPhC's pharmacy register. A legitimate prescription route will always involve a clinical assessment, there is no lawful shortcut.

Prices have shifted too. Eli Lilly's September 2025 UK price increase pushed list prices significantly higher, and private costs now vary considerably by dose and provider. For context on what a transparent, all-inclusive price covers (consultation, prescription, delivery and ongoing clinical support) it's worth looking at our treatment options page, where current pricing is set out clearly.

If you're trying to work out whether Mounjaro is right for you, the only reliable answer comes from a clinical assessment. Check your eligibility with our prescribers and find out whether treatment is appropriate for your specific situation.